Journals / Journal of Microbiology and Infectious Diseases / 2021 / Cilt: 11 - Sayı: 03

Evaluation of COVID-19 Patients with Chronic Kidney Disease

Pages
152–158
Publication Date
2021-09-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the results in Table 3, Unilateral ground-glass opacity (GGO) in the radiological findings of the Non-dialysis CKD group was significantly (P=0.50) higher than the other groups.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The present study seeks to provide insight into managing patients with chronic kidney disease (CKD) infected with COVID-19.
📊
Key Findings & Data:Methods: Patients with COVID-19 with CKD were included in the study.
💡
Conclusion & Impact:According to the results in Table 3, Unilateral ground-glass opacity (GGO) in the radiological findings of the Non-dialysis CKD group was significantly (P=0.50) higher than the other groups.
🔬Design:Review & Systematic Survey
📍Scope:2021 Verileri
⚙️Variables:COVID19 · chronic kidney disease · Dialysis

Abstract

Objectives: The present study seeks to provide insight into managing patients with chronic kidney disease (CKD) infected with COVID-19. Methods: Patients with COVID-19 with CKD were included in the study. The eligible patients were divided into four groups: 1) patients who were not on dialysis, 2) patients on maintenance dialysis, 3) patients who underwent dialysis following COVID-19, 4) patients with a history of a kidney transplant. After reviewing clinical charts, nursing records, laboratory findings, radiological reports, and other medical records of CKD patients with COVID-19 confirmed infection, clinical presentation, laboratory data, radiology findings, and results were extracted from documented medical records. The epidemiological, clinical, laboratory and outcome characteristics of the subgroups were evaluated and compared. Results: Seventy-eight patients were included into the study. Hypertension (50 cases, 72.5%), diabetes (44 cases, 63.8%), and Cardiovascular disease (26 cases, 38.2%) were the most common risk factors in the studied patients. Among all participants, 40 (52.6%) patients died. The most common symptom was dyspnea (56.6%), followed by dry cough (38.7%). Comparison of blood, inflammatory, biochemical, and clinical indices among the patients' groups show that LDH (P=0.022), AST (P=0.038), and ALT (P= 0.004) indices were significantly different between groups of patients. According to the results in Table 3, Unilateral ground-glass opacity (GGO) in the radiological findings of the Non-dialysis CKD group was significantly (P=0.50) higher than the other groups. Conclusion: It can be concluded that CKD is one of the critical factors that can cause poor prognosis in COVID-19 patients. J Microbiol Infect Dis 2021; 11(3):152-158.

🔖

Cite This Article

KESHMIRI, Y. S., MIRZAIE, S. K., SALI, S., YADEGARYNIA, D., ABOLGHASEMI, S., TEHRANI, S., ZAMANI, A., DERISI, M. M. (2021). Evaluation of COVID-19 Patients with Chronic Kidney Disease. Journal of Microbiology and Infectious Diseases, Cilt: 11 - Sayı: 03, 152–158. https://ajindex.com/articles/681389

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Estola T. Coronaviruses, a new group of animal RNA viruses. Avian diseases. 1970; 14(2):330-6
  2. Hui DS, E IA, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-6
  3. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. Jama. 2020;323(8):707-8
  4. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. 2020. https://covid19.who.int/. Accessed July 20 2020
  5. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5)
  6. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020;12(7):6049-57
  7. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Comprehensive Clinical Medicine. 2020:1-8
  8. Joanne M. Bargman, Karl L. Skorecki. Chronic Kidney Disease. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison's principles of internal medicine; 2018.p.2111-2121
  9. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020;395(10225):709-33
  10. Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. Journal of the American Society of Nephrology: JASN. 2020;31(7):1380-3
  11. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International urology and nephrology. 2020;52(6):1193-4
  12. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International. 2020;97(5):829-38
  13. Jung HY, Lim JH, Kang SH, Kim SG, Lee YH, Lee J, et al. Outcomes of COVID-19 among Patients on In-Center Hemodialysis: An Experience from the Epicenter in South Korea. J Clin Med 2020;9(6)
  14. World Health O. Clinical management of COVID-19: interim guidance, May 27 2020. Geneva: World Health Organization. 2020. https://apps.who.int/iris/handle/10665/332196. Access